Journal: bioRxiv

Article Title: Paclitaxel sensitizes TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-resistant breast cancer cells towards TRAIL-mediated apoptosis

doi: 10.64898/2026.03.18.712553

Figure Lengend Snippet: MM/PBSA binding energies and RMSD values for various molecular complexes: Left panels: TRAIL-DR5 complex (upper) and TRAIL-DCR2 complex (lower) in the absence of Paclitaxel. Middle panels: TRAIL-DR5 complex (upper) and TRAIL-DCR2 complex (lower) in the presence of paclitaxel. Right panels: Paclitaxel-DR5 complex (upper) and Paclitaxel-DCR2 complex (lower).

Article Snippet: Target proteins were identified using primary antibodies against DR5 (Cat. No.8074) and DCR2 (Cat. No.8049) from Cell Signaling Technology, USA.

Techniques: Binding Assay

Journal: bioRxiv

Article Title: Paclitaxel sensitizes TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-resistant breast cancer cells towards TRAIL-mediated apoptosis

doi: 10.64898/2026.03.18.712553

Figure Lengend Snippet: a, b Immunoblots showing protein expression of DR5 and DCR2 respectively in MDA-MB-231 cells after paclitaxel treatment at a dose of 50 nM for 24 hours. c, d Immunoblots showing protein expression of DR5 and DCR2 respectively in MCF7 cells after paclitaxel treatment at a dose of 50 nM for 24 hours. β-actin is used as an endogenous control. Densitometric graph represents mean expression value obtained from three biological repeats of every experiment whereas blot shows the representative image. * Indicates p value ≤ 0.05.

Article Snippet: Target proteins were identified using primary antibodies against DR5 (Cat. No.8074) and DCR2 (Cat. No.8049) from Cell Signaling Technology, USA.

Techniques: Western Blot, Expressing, Control

Journal: bioRxiv

Article Title: Paclitaxel sensitizes TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-resistant breast cancer cells towards TRAIL-mediated apoptosis

doi: 10.64898/2026.03.18.712553

Figure Lengend Snippet: a Immunoblot showing protein expression of DR5 and DCR2 in MCF7 cells after the treatment protocol. b Immunoblots showing protein expression of DR5 and DCR2 in MDA-MB-453 cells after the treatment protocol, β-actin is used as an endogenous control. Densitometric graph represents mean expression value obtained from three biological repeats of every experiment whereas blot shows the representative image. * Indicates p value ≤ 0.05.

Article Snippet: Target proteins were identified using primary antibodies against DR5 (Cat. No.8074) and DCR2 (Cat. No.8049) from Cell Signaling Technology, USA.

Techniques: Western Blot, Expressing, Control

Journal: bioRxiv

Article Title: Paclitaxel sensitizes TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-resistant breast cancer cells towards TRAIL-mediated apoptosis

doi: 10.64898/2026.03.18.712553

Figure Lengend Snippet: a, b Trypan blue assay showing percentage of cell death in MDA-MB-231 and MCF7 cells respectively after paclitaxel treatment at a dose of 50 nM, 100 nM and 200 nM for 6-hours, 12-hours and 24-hours. c, d Quantitative PCR showing transcript expression of DR5 in MDA-MB-231 and MCF7 cells respectively after paclitaxel treatment at a dose of 50 nM, 100 nM and 200 nM for 6-hours, 12-hours and 24-hours. e, f Quantitative PCR showing transcript expression of DCR2 in MDA-MB-231 and MCF7 cells respectively after paclitaxel treatment at a dose of 50 nM, 100 nM and 200 nM for 6-hours, 12-hours and 24-hours. Transcript analysis was done for DR5 and DCR2 in both cell lines through real time quantitative PCR (qPCR) using β-actin as an endogenous control. Graph represents mean expression value obtained from three biological repeats for every experiment. * Indicates p value ≤ 0.05.

Article Snippet: Target proteins were identified using primary antibodies against DR5 (Cat. No.8074) and DCR2 (Cat. No.8049) from Cell Signaling Technology, USA.

Techniques: Real-time Polymerase Chain Reaction, Expressing, Control

Journal: bioRxiv

Article Title: Paclitaxel sensitizes TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-resistant breast cancer cells towards TRAIL-mediated apoptosis

doi: 10.64898/2026.03.18.712553

Figure Lengend Snippet: TRAIL on binding to DR5 activates apoptosis via caspase-3. However, TRAIL-DCR2 interaction inhibits TRAIL-mediated apoptosis. Typically, TRAIL-resistant cells exhibit higher expression levels of DCR2 relative to DR5. In the absence of paclitaxel, TRAIL exhibits a greater binding affinity for the DCR2 receptor. In these resistant cells, on administration of TRAIL, the ligand (TRAIL) binds to DCR2 and suppresses apoptosis. In the presence of paclitaxel, the expression of DR5 increases while the expression of DCR2 decreases through an unidentified mechanism. Additionally, paclitaxel can physically interact with the DCR2 receptor, hence enhancing TRAIL-DR5 binding and rendering TRAIL-resistant cells susceptible to TRAIL mediated apoptosis.

Article Snippet: Target proteins were identified using primary antibodies against DR5 (Cat. No.8074) and DCR2 (Cat. No.8049) from Cell Signaling Technology, USA.

Techniques: Binding Assay, Expressing

Journal: Cell Reports Medicine

Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer

doi: 10.1016/j.xcrm.2026.102630

Figure Lengend Snippet: dDNMT activates TRAIL-death receptor signaling in VHL -deficient ccRCC cells (A) Volcano plot of SGI1027-induced and -repressed genes in RCC10 cells ( n = 2 biological replicates). FC, fold change. (B) Biocarta pathway enrichment analysis of SGI1027-induced genes in RCC10 cells. (C) RT-qPCR analysis of TNFSF10 , TNFRSF10A , TNFRSF10B , and TNFRSF10D mRNA levels in RCC10 cells treated with vehicle or SGI1027 for 2 days ( n = 3 biological replicates). (D and E) Immunoblot analysis of TRAIL, DR4, DR5, DcR2, pro-caspase-10, and cleaved caspase-10 (C-caspase-10) proteins in isogenic RCC10 cells treated with vehicle, SGI1027 (D and E, n = 2 biological replicates), MS1129 (E, n = 2 biological replicates), or decitabine (E, n = 2 biological replicates) for 2 or 7 days. (F) Global m5C levels in RCC10 cells treated with vehicle or SGI1027 for 2 days by ELISA assay ( n = 3 biological replicates). (G–J) MeDIP-qPCR assay in RCC10 cells treated with vehicle or SGI1027 for 2 days ( n = 3 biological replicates). (K–M) DNMT1, DNMT3A, and DNMT3B ChIP-qPCR assay in RCC10 cells ( n = 3 biological replicates). (N) Scheme of dDNMT-activated apoptotic pathway. Data represent mean ± SEM. p value was determined by bioinformatics with edgeR (A) or gene set enrichment analysis (B), unpaired 2-tailed Student’s t test (C and F), two-way ANOVA with Tukey’s test (G–I), and one-way ANOVA with Dunnett’s test (K–M). See also and .

Article Snippet: The following antibodies were used: anti-HIF-1α antibody (A300-286A, Bethyl Laboratories), anti-HIF-2α antibody (home-made), anti-DNMT1 antibody (24206-1-AP, Proteintech), anti-DNMT3A antibody (20954-1-AP, Proteintech), anti-DNMT3B antibody (26971-1-AP, Proteintech), anti-DNMT3L antibody (sc-393603, Santa Cruz), anti-cleaved-caspase-3 antibody (9661S, Cell Signaling Technology), anti-cleaved-caspase-7 antibody (8438S, Cell Signaling Technology), anti-PARP1 antibody (9542S, Cell Signaling Technology), anti-caspase-10 antibody (14311-1-AP, Proteintech), anti-caspase-8 antibody (13423-1-AP, Proteintech), anti-TRAIL antibody (27064-1-AP, Proteintech), anti-DR4 antibody (24063-1-AP, Proteintech), anti-DR5 antibody (69400S, Cell Signaling Technology), anti-DcR2 antibody (16781-1-AP, Proteintech), anti-β-actin (81115-1-RR, Proteintech), and anti-α-tubulin (66031-1-Ig, Proteintech).

Techniques: Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay, Methylated DNA Immunoprecipitation, ChIP-qPCR